A discussion with leading scientists at the forefront of substance use disorder and mental health research was held on March 11, 2023, at 2pm PT at the Fairmont Century Plaza in Los Angeles. View the information below.

I. Welcome: Nancy Davis, Founder and President of CAN and Isabella Rickel, CAN Board Member

II. Moderator and Introduction of Panel: Kurt Rasmussen, Ph.D., CSO Delix Therapeutics

• Topic 1: Living with Substance Use Disorder: Madison Mastera, Guest Speaker
• Topic 2: Current State of SUD/OUD Treatment: Where Are the Gaps? Kelly E. Dunn, Ph.D., Johns Hopkins University School of Medicine and Justin C. Strickland, Ph.D., Johns Hopkins University School of Medicine
• Topic 3: Living with Substance Use Disorder: Jason Wahler, CAN Board Member
• Topic 4: Overdose Protection
  1. OTC Naloxone: Judy Ashworth, M.D., SVP at Pinney Associates and CMO of Harm Reduction Therapeutics
  2. New Dangers of Fentanyl Pills and Adolescent Overdose / Tranq (Xylazine) used as an adulterant: Chris Evans Ph.D., UCLA
• Topic 5: Living with Substance Use Disorder: Brennan Ward, Guest Speaker (Via Zoom)
• Topic 6: New Therapies in the Pipeline
  1. Ibogaine as a Therapy: Deborah C. Mash, Ph.D., University of Miami School of Medicine (Via Zoom)
  2. Developing Biobehavioral Phenotyping Strategies to personalize SUD treatment: Kathryn A. Cunningham, Ph.D. University of Texas Medical Branch
  3. Ketamine as a Therapy: John H. Krystal, M.D., Yale University (Via Zoom)
  4. Development of a Single-use Medication: Courtney A. Miller, Ph.D., Scripps Research (Via Zoom)
  5. Screening for New Medications: Garret Stuber, Ph.D., University of Washington (Via Zoom)
  6. Bitter Bodyguards: How Chemosensing Can Uncover New Therapeutics: Stephanie P.B. Caligiuri, Ph.D., Icahn School of Medicine at Mount Sinai
• Topic 7: Mental Health and Substance Use Disorder: Adam Kaplin, M.D, Ph.D., CSO MyMD Pharmaceuticals

IV. Lightning Round: Answers to Submitted Questions

V. Conclusion and Thank You by Nancy Davis